Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia

Elevated levels of blood lipids are one of the major risk factors for cardiovascular (CV) disease in patients with type 2 diabetes mellitus. Diabetic dyslipidaemia is characterised by the presence of potentially atherogenic lipids, including high levels of plasma triglycerides (TGs), mild-to-moderat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Alberto Zambon
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2020
Materias:	cardiovascular risk diabetic dyslipidaemia fenofibrate low-density lipoprotein cholesterol non-high-density lipoprotein cholesterol statins triglycerides omega-3 fatty acids Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/304a140130e7415caaf4fcf0d307d221
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:304a140130e7415caaf4fcf0d307d221
record_format	dspace
spelling	oai:doaj.org-article:304a140130e7415caaf4fcf0d307d2212021-11-14T09:00:22ZNon- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia2072-03512072-037810.14341/DM10351https://doaj.org/article/304a140130e7415caaf4fcf0d307d2212020-04-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/10351https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Elevated levels of blood lipids are one of the major risk factors for cardiovascular (CV) disease in patients with type 2 diabetes mellitus. Diabetic dyslipidaemia is characterised by the presence of potentially atherogenic lipids, including high levels of plasma triglycerides (TGs), mild-to-moderately elevated levels of low-density lipoprotein cholesterol (LDL-C), and low levels of high-density lipoprotein cholesterol (HDL-C). Statin therapy to reduce LDL-C levels is the mainstay of treatment practice to reduce CV risk. However, despite achieving targets for LDL-C, patients with diabetic dyslipidaemia remain at a high risk of residual CV events. Hence there is a need to target other components (i.e. elevated TGs) of the atherogenic dyslipidaemia that are not affected by treatment with statins. This review highlights the clinical benefits of using non-HDL-C, a single marker that includes all atherogenic lipoproteins, as a leading treatment target to reduce the residual CV risk.Alberto ZambonEndocrinology Research Centrearticlecardiovascular riskdiabetic dyslipidaemiafenofibratelow-density lipoprotein cholesterolnon-high-density lipoprotein cholesterolstatinstriglyceridesomega-3 fatty acidsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 1, Pp 65-71 (2020)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	cardiovascular risk diabetic dyslipidaemia fenofibrate low-density lipoprotein cholesterol non-high-density lipoprotein cholesterol statins triglycerides omega-3 fatty acids Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	cardiovascular risk diabetic dyslipidaemia fenofibrate low-density lipoprotein cholesterol non-high-density lipoprotein cholesterol statins triglycerides omega-3 fatty acids Nutritional diseases. Deficiency diseases RC620-627 Alberto Zambon Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
description	Elevated levels of blood lipids are one of the major risk factors for cardiovascular (CV) disease in patients with type 2 diabetes mellitus. Diabetic dyslipidaemia is characterised by the presence of potentially atherogenic lipids, including high levels of plasma triglycerides (TGs), mild-to-moderately elevated levels of low-density lipoprotein cholesterol (LDL-C), and low levels of high-density lipoprotein cholesterol (HDL-C). Statin therapy to reduce LDL-C levels is the mainstay of treatment practice to reduce CV risk. However, despite achieving targets for LDL-C, patients with diabetic dyslipidaemia remain at a high risk of residual CV events. Hence there is a need to target other components (i.e. elevated TGs) of the atherogenic dyslipidaemia that are not affected by treatment with statins. This review highlights the clinical benefits of using non-HDL-C, a single marker that includes all atherogenic lipoproteins, as a leading treatment target to reduce the residual CV risk.
format	article
author	Alberto Zambon
author_facet	Alberto Zambon
author_sort	Alberto Zambon
title	Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
title_short	Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
title_full	Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
title_fullStr	Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
title_full_unstemmed	Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
title_sort	non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
publisher	Endocrinology Research Centre
publishDate	2020
url	https://doaj.org/article/304a140130e7415caaf4fcf0d307d221
work_keys_str_mv	AT albertozambon nonhighdensitylipoproteincholesterolandcardiovasculardiseaseinpatientswithdiabeticdyslipidaemia
_version_	1718429515573624832

Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia

Ejemplares similares